Site Search
Professionals 931 results
Capabilities 89 results
Practice Area
Trial skills matter—even in a world where few disputes ever see the inside of a courtroom. Winston has built a reputation as a trial lawyers’ firm, featuring seasoned litigators who leverage extensive courtroom experience to meet our clients’ business and legal objectives. Our long history of taking cases to trial—and winning—provides our clients with tremendous settlement leverage with their adversaries, as well as a substantial likelihood of a favorable resolution if, and when, they go to trial.
Industry
Insurance plays an essential role in risk mitigation for financial services companies. As risks evolve, questions often arise concerning the scope of insurance coverage and the interpretation and application of policy provisions. Winston’s insurance lawyers provide companies with best-in-class advice, corporate and transactional counsel, and, if need be, litigation defense in high-stakes coverage disputes and class actions. We have achieved excellent outcomes for our clients in matters involving a wide variety of insurance policies and claims, including cybersecurity, travel, long-term care, and annuities, among others. Moreover, we have experience in emerging issues and industries, such as blockchain technology and artificial intelligence, both of which present insurers with a unique and complicated set of risks and opportunities.
Industry
Experience 522 results
Experience
|October 10, 2025
Winston Advises Vistria Affiliate in $136M IPO of Phoenix Education Partners
A Winston & Strawn LLP team led by partners Keerthika Subramanian, Steve Gavin and Timothy Kincaid and including Jacob Tabman, Jeremy Spankowski and Jenna Smith advised TVG-I-E-AEG Holdings, LP, an affiliate of The Vistria Group, as one of the selling stockholders in the $136 million initial public offering of Phoenix Education Partners, Inc. (NYSE: PXED), the parent company of The University of Phoenix, Inc. The IPO valued Phoenix Education Partners, Inc. at approximately $1.35 billion. The transaction marks The University of Phoenix’s return to public markets after nearly a decade as a private company.
Experience
|September 23, 2025
Denali Capital Acquisition Corp Closes Business Combination with Semnur Pharmaceuticals
Winston & Strawn LLP represented Denali Capital Acquisition Corp. (OTCQB: DNQAF), a special purpose acquisition company, in the closing of its previously announced business combination with Semnur Pharmaceuticals, Inc., a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies and a majority-owned subsidiary of Scilex Holding Company (Nasdaq: SCLX).
Experience
|September 11, 2025
$1.5 Billion Raymond James Financial, Inc. Public Offering of Senior Notes
We served as underwriters' counsel to BofA Securities, Citigroup, J.P. Morgan and Raymond James, as joint book-running managers, in connection with the registered public offering of $1.5 billion of Senior Notes by Raymond James Financial, Inc. comprised of $650 million of its 4.900% Senior Notes due 2035, and $850 million of its 5.650% Senior Notes due 2055.
Insights & News 6,815 results
Sponsorship
|November 20, 2025
Winston & Strawn Sponsors 2025 Smart Business Dealmakers South Florida M&A Conference
Winston & Strawn is proud to sponsor the upcoming Smart Business Dealmakers South Florida M&A Conference. The conference brings together hundreds of local dealmakers, including middle-market CEOs, top investors and lenders, and leading M&A advisers.
Sponsorship
|November 12, 2025
Winston & Strawn Sponsors 2025 Smart Business Dealmakers Houston M&A Conference
Winston & Strawn is proud to sponsor the upcoming Smart Business Dealmakers Houston M&A Conference. The conference will discuss topics ranging from raising capital to alternative asset investing, covering the breadth of the M&A landscape.
Sponsorship
|October 22, 2025
Winston & Strawn Sponsors the 2025 Eastern District of Texas Bench Bar Conference
Winston & Strawn is a proud sponsor of the 2025 Eastern District of Texas Bench Bar Conference, one of the nation’s top annual bench bar conferences. The conference brings together judges, lawyers, topic speakers, guests, and other participants from across the world to discuss a broad range of cutting-edge legal topics.
Other Results 130 results
Law Glossary
What Is the Patent Trial and Appeal Board?
The Patent Trial and Appeal Board (PTAB) is a tribunal within U.S. Patent and Trademark Office. The PTAB oversees trial proceedings, namely: inter partes review (IPR), post-grant review (PGR), covered business method (CBM) review, and derivation proceedings. The Board also hears appeals from adverse patentability decisions by patent examiners in original applications, reissues, and reexaminations. And, while phasing out since the passage of the America Invents Act (AIA) in 2011, the PTAB is also responsible for deciding interferences. The PTAB was previously referred to as the Board of Patent Appeals and Interferences and was renamed by the AIA.
Law Glossary
What Exclusivity Periods Are Associated with Biosimilars?
An applicant may not submit an aBLA until four years after the reference product is licensed by the FDA. (See BPCIA § 351(k).) Further, any biosimilar licenses “may not be made effective” until 12 years after the reference product was licensed. (See BPCIA § 351(l).)